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ABSTRACT:  
 
 
Introduction 
In CF, people with higher FEV1 are less aggressively treated with intravenous (IV) antibiotics, with 
resultant negative impact on their health outcomes. This could be entirely clinician-driven, but patient 
choice may also influence IV use. In this prospective observational study, we explored IV 
recommendations by clinicians and IV acceptance by adults with CF to understand how clinical 
presentations consistent with exacerbations resulted in IV use.   
 
Methods 
Clinical presentations consistent with exacerbations, IV recommendation by clinicians and IV 
acceptance by patients were prospectively identified for every adult with CF in Sheffield throughout 
2016, excluding those who had lung transplantation (n=7) or on ivacaftor (n=13). Relevant 
demographic data, e.g. %FEV1, were extracted from medical records. Multi-level mixed-effects 
logistic regression models were used to compare IV recommendations vs non-recommendations for 
all clinical encounters, and IV acceptance vs non-acceptance for all IV recommendations.  
 
Results 
Among 186 adults (median age 27 years, median FEV1 78.5%), there were 434 exacerbation events 
and 318 IV use episodes following 1010 clinical encounters. Only 254 (58.5%) of exacerbations were 
IV treated. A diagnosis of exacerbation, higher number of symptoms and lower %FEV1 were 
independent predictors for IV recommendation by clinicians. Higher number of symptoms and lower 
%FEV1 were also independent predictors for IV acceptance by adults with CF. 
 
Conclusions 
Lower IV use among adults with higher %FEV1 was influenced by both clinicians’ and patients’ 
decisions. Using IV antibiotics as an exacerbation surrogate could under-estimate exacerbation 
rates and conceal differential treatment decisions according to varying clinical characteristics.  
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1. INTRODUCTION 
 
In CF, “pulmonary exacerbations” are episodic acute events causing lung damage, usually 
precipitated by infection and manifest as acute worsening of symptoms and/or drop in lung function 
(FEV1) [1, 2]. Exacerbations are associated with excess mortality, accelerated FEV1 decline, lower 
quality of life and higher healthcare costs [3]. They may also be the primary driver of progressive 
lung disease in CF [4]. There is no consensus regarding the definition and diagnosis of exacerbations 
[1], though on-going innovative studies such as STOP2 attempt to identify the best exacerbation 
treatment practices [5]. Not surprisingly, there are currently differing thresholds to initiate treatment 
and variations in treatment choices [6-11]. Prompt and aggressive treatments of exacerbations are 
nonetheless important – initiating additional antibiotics is associated with FEV1 recovery [12] and 
intravenous (IV) antibiotics tend to give the best outcomes [13].  
 
The Epidemiologic Study of CF (ESCF) showed that children with higher FEV1 were less 
aggressively treated with IV antibiotics when presenting with acute FEV1 decline which may indicate 
an exacerbation [14]. A similar study has not been done among adults. Also, it remains unclear as 
to what extent IV treatment is influenced by the decisions of children with CF, their parents or clinical 
teams. People with CF may refuse treatment [15, 16] and perceive exacerbations differently from 
clinicians [17]. Indeed, multiple steps are needed before IV treatment is initiated (see Figure 1) and 
each link in this chain is susceptible to variation. 
 
We aim to prospectively sample the links in the exacerbation-treatment chain and to understand the 
relationship between exacerbations, symptoms, other clinical characteristics and IV treatments 
among adults with CF. We therefore set out to determine the factors that influenced IV 
recommendation by clinicians during clinical encounters and IV acceptance by adults with CF. We 
also quantified the frequency of presentations consistent with exacerbations in our centre throughout 
2016 and compared the rates of exacerbation events against IV treatments.  
 
 
2. MATERIAL AND METHODS 
 
This single-centre prospective observational study included all adults with CF in Sheffield diagnosed 
according to the UK CF Trust criteria [18], excluding those who had lung transplantation (n=7) or on 
ivacaftor (n=13). These adults were excluded because both treatments have transformative effects 
on lung health, such that exacerbation rates no longer represent that of a typical adult with CF [19, 
20]. Regulatory approval for this study was obtained from NHS Health Research Authority (IRAS 
number 210313). 
 
Exacerbation data were prospectively collected between 1st January and 31st December 2016. 
During every encounter involving clinician review, exacerbations were diagnosed on clinical grounds 
by experienced CF physicians. The presence of Fuchs’ features [21], clinicians’ recommendation for 
IV treatment and patients’ acceptance of IV treatment were also recorded during every clinical 
encounter. Demographic (age, gender, genotype, pancreatic status, CF related diabetes, 
Pseudomonas aeruginosa status) and clinical (body mass index, FEV1 and IV antibiotics episodes) 
data were collected by two investigators (HZH and RC / HZH and NRB) independently reviewing 
paper notes and electronic records. Where data from two investigators differed, both investigators 
re-reviewed the original data and arrived at a consensus to ensure data accuracy [22].  
 
Sequential IV use separated by <7 days was combined and counted as a single episode [23]. 
Negative binomial regression was used to analyse exacerbation and IV use events, since these are 
count data with over-dispersion (~40% of the population have no IV use over a 1-year period [24]). 
Previous studies have demonstrated the suitability of negative binomial regression in handling this 
type of data [25] and it was also used in recent landmark CF-related clinical trials [20, 26]. %FEV1 
was calculated using Global Lung Function Initiative equations [27]. Best %FEV1 (highest reading in 
the calendar year of 2016 for each participant) was used for analysis since it is most reflective of the 
true baseline %FEV1 [14].  
 
Cohort characteristics and clinical parameters during clinical encounters were described. Factors 
associated with IV treatments were explored using mixed-effects modelling (random effect at 
individual level) to account for within-subject serial correlation because participants had >1 clinical 
encounter during 2016. Binary logistic regression was used to compare clinical encounters in which 
clinicians recommended IV vs IV not recommended. Among all encounters in which IV treatment 
were recommended, IV acceptance by adults with CF vs IV not accepted were similarly compared.  
 
The multi-level mixed-effects binary logistic regression models were fitted with clinicians’ diagnosis 
of exacerbation, number of Fuchs’ features, season of clinical encounter, %FEV1 categories, 
pancreatic status, P. aeruginosa status and gender as fixed effect. Presence of exacerbation and 
number of Fuchs’ features (as a proxy for the severity of exacerbation symptoms) would be expected 
to influence treatment decisions. Other covariates were chosen based on previous studies. IV 
treatments were more common during winter months [28]. People with higher FEV1 were less 
aggressively treated with IV antibiotics [14]. IV use was consistently associated with pancreatic 
status, P. aeruginosa status, gender and %FEV1 in recent UK registry analysis.[24] %FEV1 were 
categorised as <40%, 40- DQG , since these are internationally accepted to reflect 
different states of lung health [29] and are also applicable to UK data [24].  
 
SPSS v25 (IBM Corp) was used for analyses. P-value <0.05 was considered statistically significant. 
A complete case approach was used for analyses since the only missing data was FEV1 in one 
participant. The sample size of this study was pragmatic. There were >10 events per covariate 
included in both logistic regression models, which should represent adequate power [30]. 
 
 
 
2.1 Sensitivity, subgroup and further analyses 
Clinical encounters among the participants can be broadly divided into reviews whereby IV 
treatments were pre-agreed prior to face-to-face encounters (e.g. direct hospital admissions) and 
reviews whereby treatment decisions were made following face-to-face encounters (e.g. routine 
clinics). All clinical encounters were included in the main analyses since regardless of the 
presentation route, ultimately clinicians would still have to offer treatments that were accepted by 
participants for the initiation of any IV treatments. To understand potential bias from pre-agreed 
treatments, a sensitivity analysis of IV recommendations and acceptance excluding data for direct 
hospital admissions was reported in Appendix B. Irrespective of indication (e.g. to treat exacerbation 
or ‘elective IV’ [31]), all IV recommendations were included in the main analyses for a comprehensive 
understanding of IV use epidemiology. Appendix C specifically explored IV treatment of 
exacerbations, including looking at relevant presenting features [14, 32]. In light of the findings from 
our analyses, Appendix D compared exacerbation and IV use frequencies against %FEV1 to 
highlight their discrepancies. Appendix E reported a subgroup analysis involving adults with objective 
nebuliser adherence data to explore the potential association between adherence and IV 
acceptance. 
 
 
3. RESULTS 
 
This study included 186 adults (90, 48.4% were females), with median age 27 years (IQR 21-34 
years) and median %FEV1 78.5% (IQR 58.5-89.6%); see Table 1. Among them, 63 (33.9%) did not 
receive IV antibiotics in 2016 but only 36 (19.4%) had no detectable exacerbations. The mean 
number of IV courses/adult/year was 1.7 (95% CI 1.4-2.0), whilst the mean number of 
exacerbations/adult/year was 2.3 (95% CI 2.0-2.8).  
 
Figure 2 shows the incomplete overlap between exacerbation and IV use. Figure 3 summarises the 
clinical parameters during clinical encounters. Following 1010 clinical encounters, 434 exacerbation 
events were detected and 318 IV courses were initiated. Of those IV courses, 64 (20.1%) were not 
for exacerbations. IV antibiotics were also used prophylactically (e.g. pre-surgery), to control chronic 
infection/inflammation or for eradication (e.g. M. abscessus). IV were actually recommended on 388 
occasions but declined by participants on 74 occasions (19.1%). Only 254 (58.5%) of detected 
exacerbations were IV treated. 
Table 1: Demographic and clinical characteristics of the study subjects  
 
Excluded 
      Lung transplantation, n 
      On ivacaftor, n 
 
Included, n 
 
 
 
7 
13 
 
186 
 
 
Age in years, median (IQR) 
 
Female, n (%) 
 
Genotype status: ¶ 
      XQNQRZQPXWDWLRQVn (%) 
      FODVV,9-V mutation(s), n (%) 
      Homozygous class I-III, n (%) 
 
Pancreatic insufficient, † n (%) 
 
CF related diabetes, ‡ n (%) 
 
P. aeruginosa status: § 
      No P. aeruginosa, n (%) 
      Intermittent P. aeruginosa, n (%) 
      Chronic P. aeruginosa, n (%) 
 
BMI, median (IQR) 
 
Best %FEV1,  median (IQR) 
 
 
27 (21 to 34) 
 
90 (48.4) 
 
 
15 (8.1) 
34 (18.3) 
137 (73.7) 
 
145 (78.0) 
 
54 (29.0) 
 
 
78 (41.9) 
29 (15.6) 
79 (42.5) 
 
23.2 (20.4 to 26.0) 
 
78.5 (58.5 to 89.6) 
 
IV days 
      Mean (95% CI) )’ 
      Median (IQR) 
       
IV use episodes  
      0, n (%)  
      1, n (%) 
      2, n (%) 
      3, n (%) 
      4, n (%) 
      , n (%) 
      Mean (95% CI) )’ 
      Median (IQR) 
 
Exacerbation events 
      0, n (%)  
      1, n (%) 
      2, n (%) 
      3, n (%) 
      4, n (%) 
      , n (%) 
      Mean (95% CI) )’ 
      Median (IQR) 
 
 
 
26.2 (22.4 to 30.0) 
14 (0 to 40) 
 
 
63 (33.9) 
48 (25.8) 
27 (14.5) 
16 (8.6) 
9 (4.8) 
23 (12.4) 
1.7 (1.4 to 2.0) 
1 (0 to 3) 
 
 
36 (19.4) 
43 (23.1) 
37 (19.9) 
25 (13.4) 
14 (7.5) 
31 (16.7) 
2.3 (2.0 to 2.8) 
2 (1 to 3) 
 
¶
 Genotype status was defined according to international consensus [33]. Homozygous class I-III mutations indicate ‘severe 
genotype’. 
 
†
 3DQFUHDWLFLQVXIILFLHQF\ZDVGLDJQRVHGE\WKHFOLQLFDOWHDPRQWKHEDVLVRIIDHFDOSDQFUHDWLFHODVtase levels <200µg/g stool 
and symptoms consistent with maldigestion and malabsorption, in accordance to the UK Cystic Fibrosis (CF) Trust guideline. 
 
‡
 CF related diabetes was diagnosed by the clinical team on the basis of oral glucose tolerance test and continuous 
subcutaneous glucose monitoring results, in accordance to the UK CF Trust guideline. 
 
§
 P. aeruginosa status was determined according to the Leeds criteria [34]. 
 
 One of the study subjects did not provide any %FEV1 readings due to the inability to perform spirometry. 
 )’ The mean and 95% confidence intervals are calculated using a negative binomial regression model. 
Table 2: Summary of results from the multi-level mixed-effects binary logistic regression models (random effect at individual level, to account for 
repeated measures within an individual) for IV recommendation by clinicians and for IV acceptance by adults with CF 
 
 
 
 
Predictors 
 
Comparing IV recommended vs IV not 
recommended by clinicians among all  
1010 clinical encounters (in 186 adults) ȥ 
 
 
Comparing IV accepted vs IV not accepted 
by adults with CF among all 388 
recommended courses of IV (in 128 adults) )’ 
Adjusted odds ratio † (95% CI) P-value Adjusted odds ratio ‡ (95% CI) P-value 
 
Diagnosed as exacerbation ¶ by clinicians 
 
)XFKV¶VFRUH 
 
Season of clinical encounter (Winter as reference) 
        Autumn – Sep, Oct, Nov 
        Summer – Jun, Jul, Aug 
        Spring – Mar, Apr, May 
 
FEV1 categories DVUHIHUHQFH 
        40 – 69.9% 
        <40% 
 
Pancreatic insufficient 
 
P. aeruginosa status § (no P. aeruginosa as reference) 
        Intermittent P. aeruginosa infection 
        Chronic P. aeruginosa infection 
 
Female 
 
 
8.46 (5.59 to 12.79) 
 
3.85 (2.40 to 6.17) 
 
 
0.32  (0.20 to 0.51) 
0.38  (0.23 to 0.62) 
0.29  (0.18 to 0.48) 
 
 
1.80 (1.12 to 2.79) 
1.71 (0.90 to 3.25) 
 
5.75 (2.87 to 11.50) 
 
 
2.76  (1.48 to 5.13) 
2.48  (1.52 to 4.04) 
 
1.17 (0.78 to 1.76) 
 
< 0.001 
 
< 0.001 
 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
 
0.021 
0.009 
0.100 
 
< 0.001 
 
< 0.001 
0.001 
< 0.001 
 
0.454 
 
1.08 (0.49 to 2.39) 
 
2.64 (1.30 to 5.35) 
 
 
0.24  (0.10 to 0.55) 
0.12  (0.05 to 0.27) 
0.17  (0.07 to 0.41) 
 
 
2.48 (1.20 to 5.12) 
7.86 (2.03 to 30.40) 
 
0.33 (0.04 to 2.98) 
 
 
1.48  (0.45 to 4.89) 
0.61  (0.25 to 1.48) 
 
1.04 (0.53 to 2.06) 
 
0.856 
 
0.007 
 
< 0.001 
0.001 
< 0.001 
< 0.001 
 
0.002 
0.014 
0.003 
 
0.323 
 
0.176 
0.523 
0.278 
 
0.906 
 
ȥ
 For this model: Akaike Corrected Information Criterion (AIC) = 5213.2; Bayesian Information Criterion (BIC) = 5218.1 
 
)’ For this model: Akaike Corrected Information Criterion (AIC) = 1981.0; Bayesian Information Criterion (BIC) = 1984.9. 
 
† Odds ratios from this multivariate analysis are adjusted for all the other covariates as listed in Table 2. For example, the adjusted odds ratio for clinicians' diagnosed exacerbation 
WDNHVLQWRDFFRXQW)XFKV¶VFRUHVHDVRQ)(91 category, pancreatic status, P. aeruginosa and gender. Adjusted odds ratio >1 meant higher odds of clinicians recommending a 
course of IV during clinical reviews. 
 
‡ Odds ratios from this multivariate analysis are adjusted for all the other covariates as listed in Table 2. For example, the adjusted odds ratio for clinicians' diagnosed exacerbation 
WDNHVLQWRDFFRXQW)XFKV¶VFRUHVHDVRQ)(91 category, pancreatic status, P. aeruginosa status and gender. Adjusted odds ratio >1 meant higher odds of adults with CF accepting 
a course of IV recommended by clinicians. 
 
¶
 IV antibiotics were also used for non-exacerbation episodes, e.g. to arrest persistent FEV1 decline due to uncontrolled chronic infection / inflammation.  
 
§
 P. aeruginosa status was determined according to the Leeds criteria [34]. 
 
Clinicians recommended IV treatments in 388 (38.4%) of 1010 clinical encounters. A clinical 
GLDJQRVLVRIH[DFHUEDWLRQSUHVHQFHRI)XFKV¶IHDWXUHVencounters during winter, lower FEV1, 
pancreatic insufficiency and presence of P. aeruginosa were independent predictors for IV 
recommendation by clinicians. The odds of IV recommendation were 80% higher (95% CI 12-179%) 
for adults with FEV1 40-69.9% compared to FEV1 HYHQDIWHU WDNLQJ LQWRDFFRXQWDFOLQLFDO
diagnosis of exacerbation and symptom severity (see Table 2). Of 388 IV recommendations, 314 
ZHUHDFFHSWHG3UHVHQFHRI)XFKV¶IHDWXUHVHQFRXQWHUVGXULQJZLQWHUDQGORZHr FEV1, 
but not clinicians’ diagnosed exacerbations, were independent predictors for IV acceptance. The 
odds of IV acceptance were 148% higher (95% CI 40-412%) by adults with FEV1 40-69.9% 
compared to FEV1 VHH7DEOH 
 
Contingency tables showing the distribution of covariates according to IV recommendations and 
acceptance, including all univariate analyses are available in Appendix A. The results in Table 2 are 
broadly similar to the results of sensitivity analyses for IV recommendations and acceptance 
following non-inpatient reviews (see Appendix B). Even after accounting for relevant presenting 
symptoms (worsening cough, new/worsening haemoptysis, new crackles on auscultation, acute 
FEV1 decline [32]), baseline %FEV1 remains an important determinant of IV treatments for 
exacerbations (see Appendix C). The differential impact of %FEV1 on exacerbation rates and IV use 
is demonstrated in Appendix D. Among the subgroup of adults with objective nebuliser adherence 
data, there is a trend of increasing IV acceptance with increasing adherence levels (see Appendix 
E).  
 
 
4. DISCUSSION 
 
This study demonstrated that exacerbations are common, even among adults with relatively high 
baseline %FEV1. Many exacerbations (41.5%) were not IV treated, which is consistent with previous 
studies. ESCF data showed that only ~50% of exacerbations characterised by three/four Rabin 
criteria and ~2/3 of people with acute FEV1 decline >10% were treated with additional antibiotics [9, 
12]. We extended previous studies by explicitly collecting data of IV recommendation by clinicians 
and IV acceptance by adults with CF. We found that clinicians did not always recommend IV 
treatment for exacerbations and not all IV recommendations were accepted, but the factors 
associated with these decisions were somewhat different. Clinicians’ diagnosis of exacerbation and 
CF prognostic markers (e.g. P. aeruginosa status) were associated with IV recommendations but 
not with IV acceptance. The difference may be partly due to clinicians only recommending IV 
treatments that are absolutely indicated and likely to be accepted. Yet 19% of all recommended IV 
courses were still declined, suggesting imperfect treatment targeting by clinicians. In all analyses, 
higher %FEV1 were associated with lower odds of IV recommendation by clinicians and IV 
acceptance by patients. Among clinicians, low baseline %FEV1 might be considered a risk factor for 
treatment failure [35], hence the decision to recommend the most potent treatment. Among adults 
with CF, analyses in Appendix C suggest that IV acceptance is probably moderated by the 
experience and perception of symptoms, which can vary according to %FEV1 [36]. Previous ESCF 
analyses have highlighted that less aggressive IV treatments of children with higher FEV1 may 
contribute to accelerated FEV1 decline [12, 14]. Our study showed that less aggressive IV treatments 
are influenced by both clinicians and people with CF. Therefore, attempts to improve outcomes by 
improving IV utilisation should focus on the behaviours of both clinicians and patients.    
 
Our findings also suggest that directly capturing data regarding specific changes in clinical status 
that indicate an exacerbation may yield a more accurate epidemiological estimate of exacerbation 
frequencies. Current estimates are usually derived from CF registries or other medical databases 
e.g. commercial insurance databases [13, 37], which capture episodes of exacerbations indirectly 
by recording prescription of additional antibiotic treatments as a surrogate. Consequently, 
exacerbation events could only be captured if they were diagnosed and then triggered clinicians to 
offer treatments that were accepted by people with CF. Non-initiation of treatment does not 
necessarily indicate an absence of exacerbation, hence treatment data are likely to under-estimate 
exacerbation rates. Using treatment data as a surrogate may also result in spurious findings, since 
treatment data conflate differential treatment decisions and not all IV courses would be initiated for 
exacerbations. For example, 62.9% of IV courses were initiated during winter months yet only 48.6% 
of exacerbations occurred then.  
 
Exacerbation is often used as an endpoint [3] and the limitations of treatment data as a surrogate in 
CF-related studies is worth considering. In blinded randomised drug trials, between-group 
differences in exacerbation treatments might be predominantly driven by differences in exacerbation 
rates. This may not be the case in observational studies where several factors can increase the 
recommendation and uptake of exacerbation treatments, even when the frequency and severity of 
exacerbations remain constant. A similar issue might arise in non-blinded trials where the evaluated 
interventions might influence behaviour. The therapeutic relationship between patients and the 
clinical team is likely to be a key ingredient influencing medication adherence [38, 39]. The rapport 
between patients and the clinical team is also likely to influence the uptake of IV treatments (which 
W\SLFDOO\GLVUXSWGDLO\URXWLQHIRUGD\V. The analyses in Appendix E provided tentative evidence 
that adults with higher nebuliser adherence were more willing to accept IV recommendations. On 
the background of general under-recognition and under-treatment of exacerbations, better 
engagement could uncover many more exacerbations that were otherwise unrecognised. This is not 
to say that better engagement causes more exacerbations; the resultant increased detection or 
treatment of exacerbations is simply an example of ascertainment bias. This awareness is important 
when studying the relationships between medication adherence and health outcomes in CF. 
 
A strength of this study is the low risk of selection bias with the inclusion of all eligible adults in 
Sheffield. This study does have several limitations. A single-centre study may lack generalisability 
since there is between-centre variation in IV treatments [40]. Replication of findings with pre-
specified analyses in larger prospectively collected datasets would be desirable. Nonetheless, our 
findings are consistent with previous studies (e.g. ESCF data also identified less aggressive IV 
treatment among people with higher FEV1). It is also not possible to detect every exacerbation with 
6-12 weekly clinic reviews. More exacerbations may well be detected with more intensive 
monitoring.[41] The exacerbation rates in our cohort (mean of 2.3 events/adult/year) is high, yet it is 
still likely to be an under-estimation. This does not necessarily diminish the significance of our 
findings. It is more likely for exacerbation events to be missed among those with higher FEV1 (since 
people with lower FEV1 are more symptomatic during exacerbations [14]), which means there could 
be even less discrepancy in exacerbation events between different %FEV1 categories in our cohort 
if exacerbations were not selectively missing. Another limitation is that exacerbation frequency does 
not account for the severity of each exacerbation event. A person on IV antibiotics continuously 
throughout the calendar year would only be considered to have a single exacerbation event and a 
single IV use episode based on the definition applied in this study. Counting sequential IV use 
separated by <7 days as a single episode (as per international convention [23, 42]) may selectively 
under-estimate both exacerbations and IV use among people with lower FEV1, but it is unlikely to 
cause differential under-estimation of exacerbation events vs IV use episodes. We also did not 
examine the role of respiratory viruses (which have been shown to increase both the risk of 
exacerbations [43] and IV treatments [28]) and did not collect patient-reported symptoms in our 
study. It might be useful for future studies to explicitly screen patients for respiratory viruses and to 
use instruments such as the CF Respiratory Symptom Diary-Chronic Respiratory Infection Symptom 
Score (CRISS) [44] to collect data on patient-reported symptoms.   
 
 
5. CONCLUSIONS 
 
Exacerbations are common among adults with CF and a substantial proportion of these events may 
not be IV treated. In particular, people with higher FEV1 were less aggressively treated with IV 
antibiotics due to both clinicians’ and patients’ decisions. Due to discrepancies between 
exacerbations and IV use, solely relying on IV episodes as an exacerbation surrogate will under-
estimate the frequency of exacerbations and conceal differential treatment decisions according to 
varying clinical characteristics. Accurate measurement of exacerbations remains challenging 
because it relies on the recognition of these events in the absence of a universally accepted 
definition. An awareness of the current limitations in detecting exacerbations are important for clinical 
management and trial design in CF. More work is needed to determine how to capture the most 
pertinent data for detecting exacerbations and to streamline treatment decisions of exacerbations.  
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Figure 1: the steps between exacerbation occurring and the initiation of IV antibiotics 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Exacerbation occurs 
1. Adults with CF: 
 
Present for clinical assessment / do not present 
2. Clinicians: 
 
Decide if exacerbation / not exacerbation 
Decide to recommend treatment / not recommend treatment 
3. Adults with CF: 
 
Accept recommended treatment / not accept 
IV antibiotics (or other treatments) initiated 
Figure 2: The relationship between exacerbation events and IV antibiotics use episodes 
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†
 In all episodes in which clinicians diagnosed exacerbations on clinical ground but felt IV treatments were not indicated, oral antibiotics 
were recommended instead. 
 
Figure 3: Clinical parameters during clinical encounters ¶ and the season of these encounters  
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¶
 The figures presented do not account for correlated data from repeated measures within an individual. 
 
†
 Exacerbations were diagnosed on clinical grounds by experienced CF physicians during all clinical reviews, although the diagnoses 
were guided by the Fuchs’ criteria. A person with acute FEV1 decline of up to 9% and otherwise reported no symptoms would have 
no Fuchs’ feature, but could still be diagnosed as having an exacerbation. 
 
‡
 FEV1 data were missing for five clinical encounters because a participant did not provide any %FEV1 readings due to the inability to 
perform spirometry. 
Appendix A: Contingency tables showing the distribution of covariates listed in Table 2 of the main manuscript for all clinical encounters / 
IV recommendations, and results of the univariate analyses for the covariates  
 
Table A.1: Contingency table and summary of results from the mixed-effects binary logistic regression model (random effect at individual level to account 
for repeated measures within an individual) for IV recommendation by clinicians among all 1010 clinical encounters (in 186 adults) 
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† The contingency table does not account for correlated data from repeated measures within an individual. 
 
‡ Crude odds ratio presented for univariate analyses. Odds ratio >1 meant higher odds of clinicians recommending a course of IV during clinical reviews. 
 
¶ One of the study subjects did not provide any %FEV1 readings due to the inability to perform spirometry, hence %FEV1 are missing for five of the clinical encounters (IV treatment was 
recommended in one of the encounters). 
Table A.2: Contingency table and summary of results from the mixed-effects binary logistic regression model (random effect at individual level to account 
for repeated measures within an individual) for IV acceptance by adults with CF among all 388 recommended courses of IV (in 128 adults) 
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† The contingency table does not account for correlated data from repeated measures within an individual 
 
‡ Crude odds ratio presented for univariate analyses. Odds ratio >1 meant higher odds of adults with CF accepting a course of IV recommended by clinicians. 
 
¶ One of the study subjects did not provide any %FEV1 readings due to the inability to perform spirometry, hence %FEV1 are missing for one of the recommended IV courses (IV recommendation 
was accepted in that encounter). 
 
 
 
Appendix B: Sensitivity analyses of IV recommendation by clinicians and IV acceptance by adults with CF following non-inpatient reviews  
 
Among the 318 IV courses used throughout 2016, 156 (49.1%) courses were initiated following non-inpatient reviews (e.g. routine outpatient clinics, ad hoc ward 
reviews and home visits) whilst the remaining courses were initiated for direct hospital admissions whereby IV treatments had already been pre-agreed prior to a 
face-to-face clinical review (see Figure B.1). It could be argued that decision making by clinicians and adults with CF during pre-agreed direct hospital admissions 
for IV treatments (in which the IV acceptance rate was 100%) may differ from non-inpatient reviews (in which IV treatments have not been pre-agreed, hence IV 
acceptance rate was only 68%).  
 
Figure B.1: The relationship between exacerbation events and IV antibiotics use episodes, stratified according to the route of presentation  
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To understand the impact of IV courses that were initiated for direct hospital admissions on the 
results, the analyses reported in Table 2 of the main manuscript were repeated using only data from 
non-inpatient reviews (i.e. data from direct hospital admissions were excluded). These sensitivity 
analyses still showed broadly similar results to the analyses using data from all clinical encounters, 
with the only notable difference being the lack of seasonal influence (see Table B.1). 
 
Table B.1: Summary of results from the multi-level mixed-effects binary logistic regression models 
(random effect at individual level, to account for repeated measures within an individual) for IV 
recommendation by clinicians and for IV acceptance by adults with CF following non-inpatient clinical 
reviews 
 
 
 
 
 
 
 
 
 
Predictors 
 
 
Comparing IV recommended 
vs IV not recommended by 
clinicians following  
848 non-inpatient reviews  
(in 182 adults) ȥ 
 
 
Comparing IV accepted vs IV 
not accepted by adults with 
CF among 230 
recommended courses of IV 
following non-inpatient 
reviews (in 108 adults) )’ 
 
Adjusted odds 
ratio † (95% CI) 
 
P-value Adjusted odds 
ratio ‡ (95% CI) 
 
P-value 
 
Diagnosed as exacerbation by clinicians 
 
)XFKV¶VFRUH 
 
Season of clinical encounter (Winter as 
reference) 
        Autumn – Sep, Oct, Nov 
        Summer – Jun, Jul, Aug 
        Spring – Mar, Apr, May 
 
FEV1 categories DVUHIHUHQFH 
        40 – 69.9% 
        <40% 
 
Pancreatic insufficient 
 
P. aeruginosa status (no P. aeruginosa as 
reference) 
        Intermittent P. aeruginosa infection 
        Chronic P. aeruginosa infection 
 
Female 
 
 
9.84 (6.10 to 15.87) 
 
4.11 (2.43 to 6.95) 
 
 
 
1.22 (0.69 to 2.15) 
1.49 (0.82 to 2.71) 
1.09 (0.60 to 1.98) 
 
 
1.67 (1.01 to 2.77) 
0.80 (0.34 to 1.88) 
 
6.49 (2.82 to 14.92) 
 
 
 
2.67 (1.31 to 5.45) 
2.19 (1.25 to 3.83) 
 
0.87 (0.54 to 1.41) 
 
< 0.001 
 
< 0.001 
 
 
0.585 
 
0.499 
0.186 
0.769 
 
0.082 
0.047 
0.611 
 
< 0.001 
 
 
0.007 
 
0.007 
0.006 
 
0.570 
 
1.17 (0.50 to 2.75) 
 
2.77 (1.34 to 5.72) 
 
 
 
1.00 (0.40 to 2.50) 
0.50 (0.21 to 1.22) 
0.74 (0.29 to 1.87) 
 
 
2.22 (1.03 to 4.77) 
4.79 (1.11 to 20.61) 
 
0.33 (0.04 to 3.11) 
 
 
 
 
1.44 (0.42 to 4.88) 
0.52 (0.21 to 1.29) 
 
1.03 (0.50 to 2.11) 
 
0.715 
 
0.006 
 
 
0.342 
 
1.000 
0.125 
0.520 
 
0.031 
0.042 
0.036 
 
0.334 
 
 
0.093 
 
0.560 
0.156 
 
0.941 
 
ȥ
 For this model: Akaike Corrected Information Criterion (AIC) = 4405.0; Bayesian Information Criterion (BIC) = 4409.7. Of the 848 non-
inpatient reviews, IV was recommended on 230 (27.1%) occasions and not recommended on 618 (72.9%) occasions. 
 )’ For this model: Akaike Corrected Information Criterion (AIC) = 1037.6; Bayesian Information Criterion (BIC) = 1040.9. Of the 230 IV 
recommendations following non-inpatient reviews, IV was accepted on 156 (67.8%) occasions and declined on 74 (32.2%) occasions. 
 
† Odds ratios from this multivariate analysis are adjusted for all the other covariates as listed in Table B.1. For example, the adjusted odds 
UDWLRIRUFOLQLFLDQV
GLDJQRVHGH[DFHUEDWLRQWDNHVLQWRDFFRXQW)XFKV¶VFRUHVHDVRQ)(91 category, pancreatic status, P. aeruginosa 
status and gender. Adjusted odds ratio >1 meant higher odds of clinicians recommending a course of IV during clinical reviews. 
 
‡ Odds ratios from this multivariate analysis are adjusted for all the other covariates as listed in Table B.1. For example, the adjusted odds 
UDWLRIRUFOLQLFLDQV
GLDJQRVHGH[DFHUEDWLRQWDNHVLQWRDFFRXQW)XFKV¶VFRUHVHDVRQ)(91 category, pancreatic status, P. aeruginosa 
status and gender. Adjusted odds ratio >1 meant higher odds of adults with CF accepting a course of IV recommended by clinicians. 
 
Clinicians recommended IV treatments in 230 (27.1%) of the 848 non-inpatient reviews. A clinical 
GLDJQRVLVRIH[DFHUEDWLRQSUHVHQFHRI)XFKV¶IHDWXUHVORZHU)(91, pancreatic insufficiency and 
presence of P. aeruginosa in respiratory cultures were independent predictors for IV 
recommendations by clinicians. The odds of clinicians recommending IV treatments were 67% 
higher (95% CI 1% to 177%) for an adult with FEV1 40-69.9% compared to an adult with FEV1 , 
even after taking into account the presence of exacerbations and symptom severity. Of the 230 IV 
recommendations following non-LQSDWLHQW UHYLHZV   ZHUH DFFHSWHG 3UHVHQFH RI 
Fuchs’ features and lower FEV1, but not clinicians’ diagnosed exacerbation, were independent 
predictors for IV acceptance by adults with CF. The odds of IV acceptance were 122% higher (95% 
CI 3% to 377%) among adults with FEV1 40-69.9% compared to adults with FEV1 7KHUHIRUH
FEV1 still influenced clinicians’ and patients’ decisions regarding IV treatments following non-
inpatient reviews. 
 
 
  
Appendix C: Sensitivity analyses to take into account clinical features which influence the 
treatment of pulmonary exacerbations 
 
A previous analysis using Epidemiologic Study of CF (ESCF) data found that the four clinical 
characteristics most associated with treatment of pulmonary exacerbations among adults with CF 
are decline in %FEV1, new crackles on auscultation, haemoptysis and increased cough [1]. Another 
ESCF analysis, which showed that children with higher FEV1 were less likely to be treated with IV 
antibiotics following an acute FEV1 decline, was repeated among children with daily cough, daily 
sputum production and crackles on auscultation at the visit closest to acute FEV1 decline as a 
sensitivity analysis since these are the most relevant clinical characteristics in the treatment of 
exacerbations among children with CF [2]. Only one exacerbation event in our cohort was associated 
ZLWKWKHFRPELQDWLRQRIDFXWH)(9GHFOLQHRIFKDQJHLQFKHVWDXVFXOWDWLRQQHZLQFUHDVHG
haemoptysis and increased cough. Therefore, it is not possible to restrict analysis of exacerbation 
treatments to the events when all relevant clinical characteristics were present. Instead we repeated 
our main analysis using multi-level mixed-effects binary logistic regression models but fitted these 
clinical characteristics as fixed effect along with %FEV1 categories.  
 
The aim of this sensitivity analysis is to determine if %FEV1 was still independently associated with 
increased odds of clinicians recommending IV to treat exacerbations and adults with CF accepting 
those recommended IV courses. This analysis was restricted to exacerbation events only because 
symptoms most relevant to the treatment of pulmonary exacerbations are unlikely to drive treatment 
decisions of non-exacerbation events. Fuchs’ features were used for this sensitivity analysis, hence 
the minor differences compared to the clinical characteristics available in the ESCF dataset. For 
example, “absolute FEV1 GHFUHDVHGE\FRPSDUHGWRSUHYLRXVUHFRUGHGYDOXH´ZDVFROOHFWHG
IURPRXUFRKRUWDVSDUWRIWKH)XFKV¶IHDWXUHEXWUHODWLYHGHFOLQHRIZDVWKHRSWLPDOFXW-off in 
the ESCF dataset [1].  
 
In our cohort, clinicians recommended IV treatments in 308 (71.0%) of the 434 detected exacerbation 
HYHQWV3UHVHQFHRI)XFKV¶IHDWXUHVHQFRXQWHUVGXULQJZLQWHUSDQFUHDWLFLQVXIILFLHQF\SUHVHQFH
of P. aeruginosa in respiratory cultures and lower FEV1 were independent predictors for IV 
recommendations by clinicians to treat pulmonary exacerbations. After taking into account the four 
most relevant clinical characteristics that influence treatment of exacerbations among adults with CF 
[1], the odds of clinicians recommending IV treatments were 227% higher (95% CI 28% to 738%) for 
an adult with FEV1 <40% compared to an adult with FEV1 VHH7DEOH&2I WKH ,9
recommendations for treatment of exacerbations, 253 (82.1%) were accepted by adults with CF in 
RXU FRKRUW 3UHVHQFH RI  )XFKV¶ IHDWXUHV HQFRXQWHUV GXULQJ ZLQWHU DQG ORZHU )(91 were 
independent predictors for IV acceptance. However, %FEV1 did not quite achieve statistical 
significance (p = 0.053) after taking into account the four most relevant clinical characteristics that 
influence treatment of exacerbations among adults with CF [1]. Nonetheless, there was still a clear 
trend of increasing odds for IV acceptance with lower %FEV1 (see Table C.1). For example, the odds 
of IV acceptance for exacerbations were 357% higher (95% CI 10% lower to 2207% higher) among 
adults with FEV1 <40% compared to those with FEV1  
Table C.1: Summary of results from the multi-level mixed-effects binary logistic regression models 
(random effect at individual level, to account for repeated measures within an individual) for IV 
recommendation by clinicians and for IV acceptance by adults with CF for treatment of pulmonary 
exacerbations 
 
 
 
 
 
 
 
 
 
Predictors 
 
 
Comparing IV recommended 
vs IV not recommended by 
clinicians to treat pulmonary 
exacerbations  
(in 150 adults) ȥ 
 
 
Comparing IV accepted vs IV 
not accepted by adults with 
CF among 308 
recommended courses of IV 
to treat exacerbations  
(in 116 adults) )’ 
 
Adjusted odds 
ratio † (95% CI) 
 
P-value Adjusted odds 
ratio ‡ (95% CI) 
 
P-value 
 
Covariates for the main analyses 
 
)XFKV¶VFRUH 
 
Season of clinical encounter (Winter as 
reference) 
        Autumn – Sep, Oct, Nov 
        Summer – Jun, Jul, Aug 
        Spring – Mar, Apr, May 
 
FEV1 categories DVUHIHUHQFH 
        40 – 69.9% 
        <40% 
 
Pancreatic insufficient 
 
P. aeruginosa status (no P. aeruginosa as 
reference) 
        Intermittent P. aeruginosa infection 
        Chronic P. aeruginosa infection 
 
Female 
 
 
 
 
4.71 (2.88 to 7.73) 
 
 
 
0.34 (0.18 to 0.62) 
0.22 (0.11 to 0.45) 
0.18 (0.09 to 0.34) 
 
 
2.21 (1.30 to 3.76) 
2.38 (1.03 to 5.51) 
 
4.76 (2.08 to 10.91) 
 
 
 
3.55 (1.58 to 7.94) 
1.50 (0.83 to 2.71) 
 
0.93 (0.56 to 1.53) 
 
 
 
< 0.001 
 
 
< 0.001 
 
0.001 
< 0.001 
< 0.001 
 
0.006 
0.004 
0.043 
 
< 0.001 
 
 
0.009 
 
0.002 
0.180 
 
0.760 
 
 
 
3.64 (1.69 to 7.84) 
 
 
 
0.20 (0.08 to 0.53) 
0.10 (0.04 to 0.25) 
0.15 (0.05 to 0.42) 
 
 
3.05 (1.28 to 7.23) 
7.40 (1.38 to 39.59) 
 
0.47 (0.05 to 4.52) 
 
 
 
 
2.05 (0.50 to 8.51) 
0.67 (0.24 to 1.88) 
 
0.69 (0.31 to 1.55) 
 
 
 
0.001 
 
 
< 0.001 
 
0.001 
< 0.001 
< 0.001 
 
0.007 
0.012 
0.020 
 
0.511 
 
 
0.198 
 
0.320 
0.450 
 
0.366 
 
Clinical presentations as the covariates 
 
FEV1 categories DVUHIHUHQFH 
        40 – 69.9% 
        <40% 
 
Absolute FEV1 GHFOLQHE\
compared to previous recorded value 
 
Change in chest auscultation 
 
New / increased haemoptysis 
 
Increase in cough 
 
 
 
 
 
1.67 (0.91 to 3.08) 
3.27 (1.28 to 8.38) 
 
 
6.24 (2.96 to 13.13) 
 
 
4.64 (2.17 to 9.93) 
 
1.46 (0.58 to 3.67) 
 
2.00 (1.07 to 3.75) 
 
 
 
0.027 
0.100 
0.013 
 
 
< 0.001 
 
 
< 0.001 
 
0.423 
 
0.030 
 
 
 
 
2.42 (0.98 to 5.16) 
4.57 (0.90 to 23.07) 
 
 
0.40 (0.20 to 0.79) 
 
 
3.23 (1.22 to 8.58) 
 
1.00 (0.34 to 2.95) 
 
3.72 (1.56 to 8.89) 
 
 
 
0.053 
0.066 
0.057 
 
 
0.009 
 
 
0.019 
 
0.993 
 
0.003 
 
ȥ
 For the model with covariates from the main analysis: Akaike Corrected Information Criterion (AIC) = 2045.9; Bayesian Information 
Criterion (BIC) = 2050.0. For the model which included clinical presentations as covariates: Akaike Corrected Information Criterion (AIC) 
= 2053.8; Bayesian Information Criterion (BIC) = 2057.8. 
 )’ For the model with covariates from the main analysis: Akaike Corrected Information Criterion (AIC) = 1589.7; Bayesian Information 
Criterion (BIC) = 1593.4. For the model which included clinical presentations as covariates: Akaike Corrected Information Criterion (AIC) 
= 1564.7; Bayesian Information Criterion (BIC) = 1568.4.  
 
† Odds ratios from these multivariate analyses are adjusted for all the other covariates as listed in the relevant row of Table C.1. For 
example, in the analysis using clinical presentations as covariates, the adjusted odds ratio for FEV1 category takes into account FEV1 GHFOLQHE\FKDQJHLQFKHVWDXVFXOWDWLRQQHZLQFUHDVHGKDHPRSW\VLVDQGLQFUHDVHLQFRXJK$GMXVWHGRGGVUDWLR!PHDQt higher 
odds of clinicians recommending a course of IV to treat a clinician-diagnosed exacerbation. 
 
‡ Odds ratios from these multivariate analyses are adjusted for all the other covariates as listed in the relevant row of Table C.1. For 
example, in the analysis using clinical presentations as covariates, the adjusted odds ratio for FEV1 category takes into account FEV1 GHFOLQHE\FKDQJHLQFKHVWDXVFXOWDWLRQQHZLQFUHDVHGKDHPRSW\VLVDQGLQFUHDVHLQFRXJK$GMXVWHGRGGVUDWLR!PHDQt higher 
odds of adults with CF accepting a course of IV that was recommended for the treatment of a clinician-diagnosed exacerbation. 
 
In keeping with the ESCF analysis [1], these results suggest that clinical characteristics of pulmonary 
exacerbations have an important impact on treatment decisions. However, the relative importance 
of specific clinical characteristics were perhaps perceived differently by clinicians and adults with CF. 
)RU H[DPSOH D VXEVWDQWLDO  DFXWH )(91 decline increased the odds of clinicians 
recommending IV treatments but did not prompt treatment acceptance by adults with CF. This may 
partly be due to appropriate treatment targeting by clinicians, such that clinical characteristics of 
exacerbations no longer influence the decisions by adults with CF. However, 55 (17.9%) of the 
recommended IV courses were still turned down and this included 29 (52.7%) occasions in which 
WKHUHZHUHDEVROXWHGHFOLQHLQ)(91 compared to previous readings. Therefore, the reduced 
odds of adults accepting IV in the face of substantial acute FEV1 decline probably reflect the fact that 
such decline was more likely among adults with high FEV1 (among 104 of such events during 
exacerbations, 63 i.e. 60.6% of these occurred among adults with FEV1 $GXOWVZLWKKLJK
FEV1 are probably less likely to perceive symptoms from acute FEV1 decline and are also more likely 
to turn down recommended IV courses. Indeed, previous studies indicated that adults with CF 
perceived exacerbation differently according to %FEV1 categories [3] and also have different 
perspective of what constitutes an “exacerbation” compared to clinicians [4].  
 
In summary, this sensitivity analyses indicate that clinicians were still more likely to recommend IV 
treatments for exacerbations among adults with lower baseline %FEV1 regardless of presenting 
symptoms / characteristics. There was also a trend of adults with a lower %FEV1 being more likely 
to accept IV treatments for exacerbations, although their decisions were more strongly moderated 
by the presenting symptoms / characteristics. Previous qualitative studies have suggested that 
treatment decisions by adults with CF are influenced by the symptoms they experienced and their 
perception of those symptoms [5, 6], since IV antibiotics can also cause systemic side-effects which 
are distressing [7, 8].  
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Appendix D: A further analysis to explore the impact of %FEV1 on the frequencies of 
exacerbation events and IV use episodes 
 
Given the analyses in the main manuscript, Appendix B and Appendix C have consistently 
demonstrated preferential use of IV antibiotics among people with lower %FEV1, it is worth exploring 
the discrepancies between exacerbations and IV use against %FEV1. Therefore, a negative binomial 
regression model was used to compare exacerbation and IV use frequency for the same %FEV1 
categories used in the other analyses. As discussed in the main manuscript, a negative binomial 
regression model was used due to its suitability in handling count data with over-dispersion. 
 
This analysis showed substantial increase in IV use episodes with lower %FEV1, but the increase in 
exacerbation events was less obvious. There were overlapping confidence intervals for the 
exacerbation event rates among adults with lowest and highest %FEV1, and even those with FEV1 
KDGaH[DFHUEDWLRQHYHQWV\HDUVHH7DEOH' 
 
Table D.1: Exacerbations and IV use episodes for different %FEV1 categories  
 
 
%FEV1 
categories † 
 
Clinicians’ diagnosed exacerbation events 
 
 
IV antibiotics use episodes 
 
(n = 116) 
40 – 69.9% 
(n = 51) 
<40% 
(n = 18) 
 
(n = 116) 
40 – 69.9% 
(n = 51) 
<40% 
(n = 18) 
 
Number of 
event(s), n (%) 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
 
 
 
 
27 (23.3) 
 
32 (27.6) 
 
27 (23.3) 
 
12 (10.3) 
 
6 (5.2) 
 
12 (10.3) 
 
 
 
8 (15.7) 
 
8 (15.7) 
 
8 (15.7) 
 
8 (15.7) 
 
6 (11.8) 
 
13 (25.5) 
 
 
 
1 (5.6) 
 
3 (16.7) 
 
1 (5.6) 
 
5 (27.8) 
 
2 (11.1)  
 
6 (33.3) 
 
 
 
54 (46.5) 
 
35 (30.2) 
 
11 (9.5) 
 
6 (5.2) 
 
3 (2.6) 
 
7 (6.0) 
 
 
 
8 (15.7) 
 
10 (19.6) 
 
13 (25.5) 
 
9 (17.6) 
 
3 (5.9) 
 
8 (15.7) 
 
 
 
1 (5.6) 
 
2 (11.1) 
 
3 (16.7) 
 
1 (5.6) 
 
3 (16.7)  
 
8 (44.4) 
 
Results from the 
negative binomial 
regression model: 
 
Event rate (95% CI) 
 
Rate ratio ‡ (95% CI) 
 
P-value for the rate 
ratio 
 
 
 
 
1.9 (1.5 to 2.4) 
 
1 (Reference) 
 
 
–  
 
 
 
 
2.9 (2.1 to 4.0) 
 
1.55 (1.05 to 2.28) 
 
 
0.028 
 
 
 
 
3.6 (2.1 to 6.0) 
 
1.89 (1.07 to 3.33) 
 
 
0.029  
 
 
 
 
1.1 (0.8 to 1.4) 
 
1 (Reference) 
 
 
–  
 
 
 
 
2.4 (1.7 to 3.3) 
 
2.24 (1.48 to 3.38) 
 
 
< 0.001 
 
 
 
 
3.9 (2.4 to 6.6) 
 
3.69 (2.08 to 6.56) 
 
 
< 0.001  
 
Overall event rate 
 
Overall P-value 
   
 
2.3 (2.0 to 2.8) 
 
0.043 
 
1.7 (1.4 to 2.1) 
 
< 0.001 
 
†
 One of the study subjects did not provide any %FEV1 readings due to the inability to perform spirometry 
 
‡
 Rate ratio >1 meant higher exacerbation rates. 
 
 
This analysis highlights the limitations of using treatment data as a surrogate for exacerbation 
events. Excess IV use among people with lower FEV1 is not just due to increased exacerbation rates 
but also conflates differential treatment decisions according to FEV1. The discrepancy between 
exacerbations and IV treatments may result in the misconception that the risk of exacerbations 
substantially increases with reduced %FEV1 when in fact, it is the probability of IV treatments that 
substantially increases with reduced %FEV1. 
Appendix E: A subgroup analysis of IV acceptance by adults with objective nebuliser 
adherence data 
 
Among the 186 adults with CF included in the main analyses, 102 (54.8%) adults were using I-neb® 
(which is a tamper-proof intelligent nebuliser machine that automatically and accurately logs every 
time a drug is being nebulised) as part of their routine treatment. Objective nebuliser adherence data 
are therefore available for this subgroup. This is an interesting subgroup to study because adherence 
may be a proxy for the rapport between adults with CF and the clinical team (various studies have 
suggested that medication adherence is influenced by the therapeutic relationship between patients 
and their clinical teams [1-3]), and this rapport may also influence IV acceptance by adults with CF. 
 
I-neb® is typically reserved for people who require nebulised antibiotics. In comparison to those not 
on I-neb®, adults on I-neb® had more severe phenotype as evidenced by lower %FEV1 and a higher 
proportion of pancreatic insufficiency (see Table E.1). This suggests appropriate targeting of I-neb® 
use for those with more severe lung disease, hence the higher IV use and exacerbation rates. 
 
Table E.1: Demographic and clinical characteristics of the adults using vs not using I-neb®  
 Adults on I-neb® (n = 102) Adults not on I-neb® (n = 84) 
 
Age in years, median (IQR) 
 
Female, n (%) 
 
Genotype status:  
      XQNQRZQPXWDWLRQVn (%) 
      FODVV,9-V mutation(s), n (%) 
      Homozygous class I-III, n (%) 
 
Pancreatic insufficient, n (%) 
 
CF related diabetes, n (%) 
 
P. aeruginosa status: 
      No P. aeruginosa, n (%) 
      Intermittent P. aeruginosa, n (%) 
      Chronic P. aeruginosa, n (%) 
 
BMI, median (IQR) 
 
Best %FEV1, ¶ median (IQR) 
 
 
26 (20 to 32) 
 
42 (41.2) 
 
 
2 (2.0) 
9 (8.8) 
91 (89.2) 
 
95 (93.1) 
 
32 (31.4) 
 
 
33 (32.4) 
20 (19.6) 
49 (48.0) 
 
23.2 (20.6 to 25.4) 
 
76.4 (62.1 to 87.0) 
 
28 (22 to 35) 
 
48 (57.1) 
 
 
13 (15.5) 
25 (29.8) 
46 (54.8) 
 
50 (59.5) 
 
22 (26.2) 
 
 
45 (53.6) 
9 (10.7) 
30 (35.7) 
 
23.2 (20.0 to 27.4) 
 
80.8 (55.3 to 91.6) 
 
IV days 
      Median (IQR) 
      Mean (95% CI) )’ 
 
IV use episodes,  
      0, n (%)  
      1, n (%) 
      2, n (%) 
      3, n (%) 
      4, n (%) 
      n (%) 
      Mean (95% CI) )’ 
 
Exacerbation events 
      0, n (%)  
      1, n (%) 
      2, n (%) 
      3, n (%) 
      4, n (%) 
      n (%) 
      Mean (95% CI) )’ 
 
 
 
18 (0 to 42) 
26.9 (22.1 to 32.8) 
 
 
29 (28.4) 
27 (26.5) 
18 (17.6) 
11 (10.8) 
6 (5.9) 
11 (10.8) 
1.8 (1.4 to 2.3) 
 
 
13 (12.7) 
24 (23.5) 
19 (18.6) 
16 (15.7) 
11 (10.8) 
19 (18.6) 
2.6 (2.1 to 3.3) 
 
 
10 (0 to 33) 
25.4 (20.4 to 31.5) 
 
 
34 (40.5) 
21 (25.0) 
9 (10.7) 
5 (6.0) 
3 (3.6) 
12 (14.3) 
1.6 (1.3 to 2.2) 
 
 
23 (27.4) 
19 (22.6) 
18 (21.4) 
9 (10.7) 
3 (3.6) 
12 (14.3) 
2.0 (1.5 to 2.6) 
 
¶
 One of the study subjects not on I-neb® did not provide any %FEV1 readings due to the inability to perform spirometry. 
 )’ The mean and 95% confidence intervals are calculated using a negative binomial regression model.
Clinicians recommended IV treatments in 232 (40.6%) of the 572 clinical encounters with adults 
using I-neb®. Of the 232 IV recommendations, 179 (77.2%) were accepted by adults using I-neb®. 
In this subgroup, the presence of more symptoms did not achieve statistical significance in terms of 
independently predicting IV acceptance (p = 0.066), although the adjusted odds ratio of 2.22 were 
similar to the overall cohort (see Table E.2). Winter season and lower FEV1 remained as independent 
predictors for IV acceptance. 
 
Table E.2: Summary of results from the multi-level mixed-effects binary logistic regression models 
(random effect at individual level to account for repeated measures within an individual) for IV acceptance 
by adults with CF using I-neb®, including and excluding adherence as one of the covariates  
 
 
 
 
 
 
 
 
 
Predictors 
 
Comparing IV accepted vs IV 
not accepted by adults with CF 
using I-neb® among 232 
recommended courses of IV (in 
78 adults) ȥ, adherence not 
included as a covariate 
 
 
Comparing IV accepted vs IV 
not accepted by adults with 
CF using I-neb® among 232 
recommended courses of IV 
(in 78 adults) )’, adherence 
included as a covariate 
 
Adjusted odds 
ratio † (95% CI) 
 
P-value Adjusted odds 
ratio † (95% CI) 
 
P-value 
 
Diagnosed as exacerbation by clinicians 
 
)XFKV¶VFRUH 
 
Season of clinical encounter (Winter as 
reference) 
        Autumn – Sep, Oct, Nov 
        Summer – Jun, Jul, Aug 
        Spring – Mar, Apr, May 
 
FEV1 categories DVUHIHUHQFH 
        40 – 69.9% 
        <40% 
 
Pancreatic insufficient 
 
P. aeruginosa status (no P. aeruginosa as 
reference) 
        Intermittent P. aeruginosa infection 
        Chronic P. aeruginosa infection 
 
Female 
 
Normative adherence clusters ‡ (‘Cluster 
1’, i.e. very low adherence, as reference) 
        ‘Cluster 2’ – low adherence 
        ‘Cluster 3’ – moderate adherence 
        ‘Cluster 4’ – high adherence 
 
 
2.08 (0.76 to 5.70) 
 
2.22 (0.95 to 5.22) 
 
 
 
0.32 (0.11 to 0.94) 
0.14 (0.06 to 0.38) 
0.25 (0.09 to 0.70) 
 
 
3.37 (1.33 to 8.54) 
6.66 (1.04 to 42.50) 
 
N/A ¶ 
 
 
 
 
1.33 (0.34 to 5.30) 
0.67 (0.23 to 2.00) 
 
1.09 (0.46 to 2.62) 
 
N/A 
 
0.154 
 
0.066 
 
 
0.001 
 
0.039 
< 0.001 
0.008 
 
0.013 
0.011 
0.045 
 
 
 
 
0.473 
 
0.681 
0.474 
 
0.840 
 
 
 
2.44 (0.86 to 6.94) 
 
2.37 (0.99 to 5.69) 
 
 
 
0.32 (0.11 to 0.97) 
0.13 (0.05 to 0.35) 
0.25 (0.09 to 0.71) 
 
 
3.55 (1.37 to 9.18) 
6.17 (0.91 to 41.78) 
 
N/A ¶ 
 
 
 
 
1.42 (0.35 to 5.73) 
0.70 (0.23 to 2.10) 
 
1.21 (0.50 to 2.94) 
 
 
 
0.82 (0.28 to 2.38) 
1.96 (0.66 to 5.85) 
3.52 (0.82 to 15.11) 
 
0.094 
 
0.053 
 
 
0.001 
 
0.044 
< 0.001 
0.009 
 
0.014 
0.009 
0.062 
 
 
 
 
0.475 
 
0.623 
0.520 
 
0.672 
 
 
0.149 
 
0.708 
0.225 
0.091 
 
ȥ
 For this model: Akaike Corrected Information Criterion (AIC) = 1124.0; Bayesian Information Criterion (BIC) = 1127.4. Of the 232 IV 
recommendations for adults using I-neb®, IV was accepted on 179 (77.2%) occasions and declined on 53 (22.8%) occasions. 
 )’ For this model: Akaike Corrected Information Criterion (AIC) = 1142.1; Bayesian Information Criterion (BIC) = 1145.5. Of the 232 IV 
recommendations for adults using I-neb®, IV was accepted on 179 (77.2%) occasions and declined on 53 (22.8%) occasions. 
 
† Odds ratios from these multivariate analyses are adjusted for all the other covariates as listed in Table E.2. For example, the adjusted 
RGGV UDWLR IRUDGKHUHQFHFOXVWHUV WDNHV LQWRDFFRXQWFOLQLFLDQV
GLDJQRVHGH[DFHUEDWLRQ)XFKV¶ VFRUHVHDVRQ)(91 category, P. 
aeruginosa status and gender. Adjusted odds ratio >1 meant higher odds of adults with CF using I-neb® accepting a course of IV 
recommended by clinicians. 
 
‡ Objective adherence data from 1st January 2016 to 31st December 2016 were downloaded from I-neb® and calculated as ‘normative 
adherence’. ‘Normative adherence’ takes into account a person’s characteristics when defining the minimum required treatment regimen 
[4]. Calculation of ‘normative adherence’ involves adjusting the denominator according to P. aeruginosa status, adjusting the numerator 
by capping daily maximum nebuliser use at 100% (also accounting for doses taken after midnight), adjusting the numerator for incomplete 
doses, adjusting the numerator for device dose delivery characteristics and adjusting the numerator by accounting for dose spacing of 
inhaled antibiotics. A person with chronic P. aeruginosa infection should take at least a nebulised mucolytic and an antibiotic. Thus the 
denominator for a person with chronic P. aeruginosa infection will be at least 3 (1x dornase alfa, 2x antibiotic). If a person with chronic P. 
aeruginosa infection only agreed to use nebulised dornase alfa once daily (which is 1 nebuliser/day), even if they take every dose of their 
dornase alfa, the ‘normative adherence’ is only 33%. The detailed methods and worked examples of calculating ‘normative adherence’ 
are provided in the paper by Hoo et al [4]. Following the calculation of ‘normative adherence’, adherence data were then clustered 
according to previously described methods [5] on a 3-monthly basis (Jan-Mar 2016, Apr-Jun 2016, Jul-Sep 2016, Oct-Dec 2016).   
 
¶
 Odds ratio for pancreatic status could not be estimated in the logistic regression model because every adult using I-neb® and accepting 
IV recommendations was pancreatic insufficient. 
Therefore, there were similarities with the overall cohort in terms of the factors that influenced IV 
acceptance although the subgroup of adults using I-neb® have more severe phenotype and lung 
disease. In this subgroup, there were higher adjusted odd ratios of accepting IV recommendations 
among adults with moderate and high adherence levels, although these did not meet statistical 
significance (p = 0.149). The odds of IV acceptance were 252% higher (95% CI 28% lower to 1411% 
higher) among the subgroup of adults with high adherence (‘Cluster 4’) compared to those with the 
lowest adherence level (‘Cluster 1’). The very wide confidence intervals indicate that the sample size 
is too small to reliably detect a difference even though the effect size may be very large and clinically 
important. The multi-level model also had fewer than 10 events per covariate (53 IV rejections, seven 
covariates), which may bias the results [6]. Higher odds of IV acceptance with higher adherence 
levels were also observed in a univariate mixed-effects binary logistic regression model (see Table 
E.3). Therefore, this subgroup analysis has generated an interesting hypothesis that can be further 
tested in larger prospective datasets. 
 
 
Table E.3: Contingency table and summary of results from the mixed-effects binary logistic 
regression model (random effect at individual level to account for repeated measures within an 
individual) for IV acceptance by the subgroup of adults with CF using I-neb® 
 
 
 
 
 
Covariate of interest: 
 
Contingency table † 
 
 
Results of the univariate 
analyses 
IV declined 
 
n = 53 
 
IV accepted 
 
n = 179 
 
 
Odds ratio ‡ (95% CI) 
 
 
 
P-value 
 
 
Normative adherence clusters: 
  
        ‘Cluster 1’ – very low adherence 
        ‘Cluster 2’ – low adherence 
        ‘Cluster 3’ – moderate adherence 
        ‘Cluster 4’ – high adherence 
 
 
 
 
19 (35.8%) 
16 (30.2%) 
13 (24.5%) 
5 (9.4%) 
 
 
 
55 (30.7%) 
38 (21.2%) 
52 (29.1%) 
34 (19.0%) 
 
 
 
1 (Reference) 
0.71 (0.28 to 1.80) 
1.47 (0.54 to 3.99) 
1.98 (0.56 to 6.94) 
 
0.334 
 
 
0.467 
0.448 
0.285 
 
† The contingency table does not account for correlated data from repeated measures within an individual. 
 
‡ Crude odds ratio presented for this univariate analysis. Odds ratio >1 meant higher odds of adults with CF using I-neb® accepting 
a course of IV recommended by clinicians. 
 
 
Given the possibility that willingness to accept IV recommendations may increase as adherence 
levels improve, methods to study the relationships between medication adherence and pulmonary 
exacerbation (which is an important health outcome in CF) should be carefully considered. If 
antibiotics treatment was used as a surrogate for an exacerbation, it may be possible to observe 
“increases in exacerbation rates” which simply reflect increases in treatment uptake rather than 
actual deterioration of lung health. For accurate elucidation of the relationships between medication 
adherence and exacerbations, it may be preferable to study clinical presentations consistent with 
exacerbations instead of using treatment data as the proxy.  
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